Expanded age range for 9-valent HPV vaccine
Work Group plans and policy considerations

Lauri Markowitz, MD
Division of Viral Diseases

Advisory Committee on Immunization Practices
October 25, 2018
Policy considerations

- Should the upper age for HPV vaccine catch-up vaccination be expanded beyond current recommended ages?
  - HPV vaccine will have greatest impact when administered before onset of sexual activity and HPV exposure
  - The Work Group is still reviewing results from health economic analyses as well as other data related to this policy question
Current recommendations for HPV vaccination in the United States

- **Routine HPV vaccination at age 11 or 12 years**
  - The vaccination series can be started beginning at age 9 years

- **HPV vaccination is also recommended for the following persons if not adequately vaccinated previously**
  - Females through age 26 years
  - Males through age 21 years
  - Certain populations through age 26 years*

- **Males aged 22 through 26 years may be vaccinated**

*Men who have sex with men, transgender persons, and persons with certain immunocompromising conditions
MMWR 2014;63 (RR05)  MMWR 2015;64:300-4  MMWR 2016; 65:2105-8
Expanded age range: Work Group discussions

- Routine age
  - No change: age 11 or 12 years; vaccination can be started at age 9 years

- Routine catch-up age group
  - Harmonization of upper age for catch-up recommendation for females and males
  - Could be the current age (26 years) or different age, depending on further considerations

- Persons older than the determined catch-up age
  - Almost all Work Group members felt that *Individual Decision Making* for persons older than the routine catch-up age group could be considered
  - Through age 45 years
If *Individual Decision Making* recommended in some age groups

- What guidance to provide?
- How to communicate who might benefit?
- How to communicate the lower effectiveness in this age group?
Next steps for ACIP HPV Vaccines Work Group

- Further review of the health economic analyses
- Summarize values and acceptability in the expanded age group
- Review data for special populations
- Discuss of policy options
- Complete Evidence to Recommendations framework
- Prepare for potential vote at February 2019 ACIP meeting
Feedback from ACIP

- Catch-up vaccination age group
  - Harmonization of upper age for ‘routine’ catch-up recommendation for males/females
  - Upper age: Could be the same age (26 years) or a different age, depending on impact and health economic analyses and other considerations

- Persons older than catch-up age through age 45 years
  - Potential recommendation for *Individual Decision Making*
ACIP HPV Vaccines
Work Group

ACIP Members
Peter Szilagyi (Chair)
Jose Romero

Ex Officio Members
Jeff Roberts (FDA)
Joohee Lee (FDA)

CDC Lead
Lauri Markowitz

Liaison Representatives
Vinita Dubey (NACCI)
Linda Eckert (ACOG)
Sandra Fryhofer (ACP)
Amy Middleman (SAHM)
Chris Nyquist (AAP)
Sean O’Leary (PIDS)
Robin O’Meara (AAFP)
Patricia Whitley-Williams (NMA)
Jane Zucker (AIM)

Consultants
Joseph Bocchini
Tamera Coyne-Beasley
John Douglas
Sam Katz
Allison Kempe
Aimee Kreimer (NCI)
Debbie Saslow (ACS)
Rodney Willoughby
Rachel Winer

CDC Contributors
Jorge Arana
Harrell Chesson
Robin Curtis
Julianne Gee
Elissa Meites
Jeanne Santoli
Mona Saraiya
Shannon Stokley
Lakshmi Panagiotakogoulos
Sukumaran
Elizabeth Unger
Thank You

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.